Compare CRI & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRI | ZYME |
|---|---|---|
| Founded | 1865 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2002 | 2022 |
| Metric | CRI | ZYME |
|---|---|---|
| Price | $37.43 | $27.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $35.60 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 1.0M | 430.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 3.26 | N/A |
| Revenue | ★ $2,898,426,000.00 | $105,965,000.00 |
| Revenue This Year | $4.57 | $183.10 |
| Revenue Next Year | $1.12 | N/A |
| P/E Ratio | $11.52 | ★ N/A |
| Revenue Growth | 1.91 | ★ 38.87 |
| 52 Week Low | $24.71 | $13.60 |
| 52 Week High | $44.44 | $29.75 |
| Indicator | CRI | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 69.73 |
| Support Level | $37.18 | $22.10 |
| Resistance Level | $39.16 | $28.49 |
| Average True Range (ATR) | 1.40 | 1.02 |
| MACD | -0.20 | 0.46 |
| Stochastic Oscillator | 37.29 | 93.46 |
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.